Ryan N. McIlwain

Ryan N. McIlwain

Auto-generated profile, based on publicly available information

Ryan N. McIlwain

Department of Orthopaedic Surgery, University of Alabama at Birmingham; Birmingham, AL

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2025 in Journal of Orthopaedics
Verified
Journal Article
Closed access
MMMary Jane McConnell
Mary Jane McConnell
RLRobin M. Litten
Robin M. Litten
HBHumza Bhatti
Humza Bhatti
RMRyan N. Mcllwain
Ryan N. Mcllwain
DNDecorian D. North
Decorian D. North
JJJoey P. Johnson
Joey P. Johnson

10 April 2026 in Journal of Orthopaedic Trauma
Verified
Journal Article
Closed access
RMRyan N. BS McIlwain
Ryan N. BS McIlwain
RLRobin M. Litten
Robin M. Litten
MMMary Jane BS McConnell
Mary Jane BS McConnell
HBHumza S. Bs Bhatti
Humza S. Bs Bhatti
JEJonathan D. Ellis
Jonathan D. Ellis
CSClay A. Spitler
Clay A. Spitler
OBJECTIVES: To determine if patient resiliency is associated with patient-reported outcomes at six and twelve months following surgical fixation of acetabular fractures. METHODS: Design: Retrospective cohort study. Setting: Single Level I trauma center (2022-2024). Patient Selection Criteria: Adults who sustained an acetabulum fracture (AO/OTA 62) treated operatively and completed Brief Resilience Scale (BRS) surveys two-weeks postoperatively and Patient-Reported Outcomes Measurement Information System (PROMIS) surveys at six- and/or twelve-months postoperatively were included. Outcome Measures and Comparisons: Primary outcomes were scores for PROMIS Physical Function (PF), Global Physical Health (GPH), Global Mental Health (GMH), Pain Interference (PI), Depression, Anxiety, and Brief Resilience Scale (BRS). PROMIS scores were compared between low and high resiliency individuals at six- and twelve-months, as defined by the cohort median BRS score. Multivariable linear regression was used to adjust for relevant clinical covariates. RESULTS: A total of 111 patients were included; 81 patients (64.2% male, 60.5% white; mean age 51.1 years) completed 6-month surveys and 56 patients (75.0% male, 66.1% white; mean age 51.8 years) completed 12-month surveys. At six months, high resiliency (BRS (≥ 3.7) was independently associated with higher PROMIS PF (β = 6.73 [2.93-10.54], p < 0.001), GPH ((β = 8.88 [5.47-12.28], p < 0.001), and GMH ((β = 12.40 [8.48-16.32], p < 0.001) with lower PI ((β = -7.83 [-11.25 to -4.40], p < 0.001), Depression ((β = -15.33 [-19.69 to -10.97], p < 0.001), and Anxiety ((β = -11.54 [-16.35 to -6.72], p < 0.001) scores on regression analysis. Similarly, highly resilient (BRS ≥ 3.6) individuals completing 12-month surveys had significantly positive associations across all domains. CONCLUSIONS: Compared to patients with low resilience, high baseline resilience was associated with significantly better PROMIS outcomes at six and twelve months following acetabular fixation. LEVEL OF EVIDENCE: III

5 October 2026 in British Medical Bulletin
Verified
Journal Article
Closed access
RMRyan N McIlwain
Ryan N McIlwain
EPElizabeth R Powell
Elizabeth R Powell
RLRobin M Litten
Robin M Litten
AAAlexis N Alders
Alexis N Alders
JJJoey P Johnson
Joey P Johnson
Background: Non-union is a challenging complication following long bone fractures. Demineralized bone matrix (DBM) has been increasingly utilized, however, its role in managing long bone non-union remains unclear. This systematic review evaluates the published research on the effectiveness of DBM in treating long bone non-union. Sources of data: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, PubMed, Embase, and Scopus were searched from inception to March 2026 for studies assessing DBM use in adult long bone non-union. Areas of agreement: Eight studies including 340 patients were included. DBM was used alone or combined with autologous bone marrow concentrate (BMC), platelet-rich fibrin (PRF), platelet-rich plasma (PRP), or cancellous allograft chips. Union rates were similar when comparing DBM and iliac crest bone grafting (ICBG). DBM-treated patients achieved 79%–100% union (mean time to union between 3.7 and 11.9 months) versus 80%–100% for ICBG. Complications were minimally reported with no DBM-specific adverse events. Areas of controversy: Significant heterogeneity existed in DBM formulation, volume, and administration strategies. Studies utilized putty, strips, and injectable formulations, with volumes ranging 1–10 cc. DBM was also variably combined with PRP, BMC, or cancellous allograft chips. Outcome reporting was not standardized. Growing points: DBM appears to be an effective grafting strategy across diverse clinical applications and may offer a viable alternative to autologous grafting. Areas timely for developing research: Further high-quality randomized controlled trials with consistent outcome measures are needed to define optimal use of DBM in treating long bone non-union.

10 June 2026 in Injury
Verified
Journal Article
Closed access
JDJoseph K. Dekle
Joseph K. Dekle
CSConnor K. Sisk
Connor K. Sisk
RLRobin M. Litten
Robin M. Litten
DADoriann M. Alcaide
Doriann M. Alcaide
RMRyan N. McIlwain
Ryan N. McIlwain
JJJoey P. Johnson
Joey P. Johnson

14 November 2026 in Journal of Orthopaedic Trauma
Verified
Journal Article
Closed access
MYMatthew T. Yeager
Matthew T. Yeager
RRRobert W. Rutz
Robert W. Rutz
JDJoseph K. Dekle
Joseph K. Dekle
DADoriann M. Alcaide
Doriann M. Alcaide
RLRobin M. Litten
Robin M. Litten
CSClay A. Spitler
Clay A. Spitler
OBJECTIVE: To evaluate the impact of perioperative intravenous (IV) tranexamic acid (TXA) on total blood loss (TBL) and transfusion requirements in patients who underwent acetabular fracture fixation (OTA/AO 62) via a posterior surgical approach. The authors hypothesized that patients who received perioperative IV TXA would demonstrate lower TBL compared with those who did not receive perioperative TXA. METHODS: Design: Retrospective cohort study. Setting: Single Level I trauma center (2010–2023). Patient Selection Criteria: Adult patients who underwent acetabular fracture (OTA/AO 62) fixation through a posterior surgical approach from 2010 to 2023. Outcome Measures and Comparisons: The primary outcome was TBL among patients receiving perioperative TXA versus no TXA. Secondary outcomes were hospital length of stay, postoperative hemoglobin at 24 and 48 hours, and transfusion requirements. RESULTS: A total of 591 patients met inclusion criteria, of which 186 (31.5%) received perioperative IV TXA and 405 (68.5%) did not. The TXA group had a mean age of 39.7 years (range, 18–80 years) and included 123 male patients (66.1%), while the no-TXA group had a mean age of 38.6 years (range, 18–89 years) and included 273 male patients (67.4%). Age ( P = 0.396) and body mass index ( P = 0.489) did not differ between groups. The TXA group demonstrated a higher rate of protrusio (9.7% vs. 4.4%, P = 0.016) but lower rates of intra-articular fragments (34.9% vs. 47.2%, P = 0.006) and wall comminution (41.4% vs. 51.4%, P = 0.027). On unadjusted analysis, patients receiving TXA demonstrated shorter operative duration (171.4 vs. 188.5 minutes, P = 0.036), whereas calculated TBL did not differ between groups ( P = 0.600). On multivariable regression, perioperative TXA use was not independently associated with calculated TBL (β = 32.5 mL; 95% confidence interval, −123.2 to 188.2; P = 0.682). There were no differences in perioperative hemoglobin values (all P ≥ 0.063), intraoperative or postoperative transfusion requirements (all P ≥ 0.493), hospital length of stay ( P = 0.750), or postoperative complications, including thromboembolic events, fracture-related infection, heterotopic ossification, or all-cause mortality (all P ≥ 0.381). CONCLUSIONS: Perioperative IV TXA use was not independently associated with calculated TBL following posterior approach acetabular fracture fixation. Instead, longer operative duration and fracture-related characteristics were independently associated with greater TBL. TXA use was also not associated with differences in transfusion requirements or short-term postoperative outcomes. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.